4.10Open4.10Pre Close0 Volume51 Open Interest145.00Strike Price0.00Turnover603.19%IV43.87%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry4.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0702Delta0.0012Gamma61.22Leverage Ratio-3.3147Theta-0.0011Rho-4.30Eff Leverage0.0245Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet